SKYHAWK THERAPEUTICS
FALCON-HD

An Update for the Huntington's Disease Community: Twelve-Month Interim Data from the SKY-0515 Phase 1/2 Study

Dear friends in the Huntington's disease community,

We'd like to share an update on ongoing research into **SKY-0515,** an investigational medicine being studied for Huntington's disease (HD).

Alongside the scientific press release posted on **June 1, 2026,** we wanted to share this letter written specifically for our HD community — because you deserve clear, honest and timely updates on the progress we are making together.

We appreciate you taking the time to read this.

Understanding SKY-0515 and How It Is Being Studied

SKY-0515 is an investigational, **once-daily medicine taken by mouth** that is currently only available through clinical trials. It is not yet approved for commercial use in any disease or in any country.

The investigational medicine is designed to affect two biological factors involved in Huntington's disease:

- **Mutant huntingtin (mHTT),** the abnormal protein that causes HD
- **PMS1**, one of the proteins involved in processes linked to disease progression

Researchers are studying whether changes in these biological markers could be relevant to HD over time.

New Twelve-Month Interim Results from the Phase 1/2 SKY-0515 Study

The announcement included results from a twelve-month interim analysis of people with early-stage HD participating in an ongoing Phase 1/2 clinical study of SKY-0515.

This study is designed primarily to evaluate safety and understand how the investigational medicine behaves in the body and how the body affects the drug. Trial investigators also continue to monitor biological markers and exploratory clinical measures. Participants received either a low or a high dose of SKY-0515.

What Did Researchers Observe After One Year of Treatment?

Changes in biological markers

Researchers reported continued reductions in biological markers associated with Huntington's disease:

- Participants receiving SKY-0515 showed **dose-dependent reductions in mutant huntingtin protein** levels in blood
- At the high dose studied, average reductions of approximately **69%** were observed after twelve months
- Reductions in PMS1 mRNA of up to **26%** were also observed
- SKY-0515 continued to demonstrate **exposure to the central nervous system** including the brain, which is important for a treatment being developed for a neurological disease

These findings indicate that SKY-0515 continues to engage its intended biological targets. At this stage, researchers are still working to understand how changes in these biomarkers may relate to long-term clinical and functional outcomes.

Twelve-Month Safety Findings

- SKY-0515 has **generally been well tolerated** in the study so far
- No new significant safety concerns were reported in the twelve-month analysis
- Safety monitoring remains ongoing in all clinical studies

As with any investigational medicine, continued evaluation in larger studies is needed to further understand its safety profile.

What Did Researchers Learn About Symptoms and Daily Function?

Researchers also assessed participants using the **Composite Unified Huntington's Disease Rating Scale (cUHDRS)**, an exploratory measure that combines assessments of movement, thinking, and daily functioning.

The study reported that:

- Participants receiving SKY-0515 showed **positive average changes** from the trial starting point in cUHDRS scores at three, six, nine, and twelve months
- At twelve months, average cUHDRS scores remained 0.38 points **above baseline levels – that is, the levels which patients began at**
- Researchers compared these results with statistical analyses based on natural history data from people living with HD who were not receiving SKY-0515. The natural history i.e. the natural course of disease progression without treatment showed that patients lose 0.92 points in this test over the same twelve-month period

While these observations are encouraging, it is important to remember that this remains an early-stage study involving a relatively small number of participants. Larger, placebo-controlled studies are needed to determine whether SKY-0515 may have an effect on disease progression, symptoms, or daily functioning.

Progress Across the SKY-0515 Clinical Development Program

Phase 1/2 study

- Enrollment has been completed
- Participants continue in the blinded extension portion of the study
- Twelve-month interim data have now been reported
- The study will end after fifteen-month data are collected
- Participants who completed this study will roll into an open label study where all participants will continue receiving SKY-0515

Phase 2/3 FALCON-HD study

The global Phase 2/3 FALCON-HD program is actively underway and is designed to further evaluate SKY-0515 in a placebo-controlled study in a larger number of people living with HD.

Recent updates include:

- Enrollment in the **FALCON-HD ANZ** study has been completed in Australia and New Zealand, with 144 participants enrolled ahead of schedule
- The **FALCON-HD Worldwide** study is planning to be expanded across countries including Argentina, Brazil, Chile, Columbia, United States, Canada, UK, Germany, Spain, Georgia, and potentially Australia and New Zealand.
- More than 175 participants have now enrolled across the SKY-0515 Phase 1/2 and FALCON-HD clinical studies combined

Participants in FALCON-HD will receive SKY-0515 or placebo and will be followed to evaluate safety, biological markers, and clinical outcomes over a longer period of time.

More details are available at clinicaltrials.gov/study/NCT07378644 and FALCON-HD.com.

What Do These Twelve-Month Results Mean for the HD Community?

The twelve-month findings provide additional information about the ongoing development of SKY-0515. Researchers observed continued reductions in important biological markers and reported encouraging trends in exploratory clinical assessments over one year of treatment.

However, SKY-0515 remains an investigational treatment, and it is still too early to know whether these findings will translate into meaningful long-term benefits for people living with HD. Larger, placebo-controlled studies are underway to help answer these important questions.

We remain committed to sharing updates openly and transparently as the research progresses.

Thank You to Study Participants and the HD Community

We are deeply grateful to the individuals and families who participate in the clinical trials, as well as the investigators, study coordinators, and all those involved in the

conduct and collection of data, the advocacy organizations, and community members all of whom make this research possible.

Your commitment continues to advance the search for new treatment options for Huntington's disease.

We look forward to sharing future updates as we learn more.

With appreciation,

The Skyhawk Therapeutics Team